US approval for Vyvanse as maintenance treatment for ADHD in adults
This article was originally published in Scrip
Executive Summary
The US FDA has approved Shire's Vyvanse (lisdexamfetamine dimesylate) as a maintenance treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD).